Fermer le menu


Member of Lyonbiopole


OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new IO targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.

Our lead program, anti-CD39 antibody IPH5201, has been licensed to Innate Pharma (2016) and partnered with AstraZeneca (2018). IPH5201 is now entering phase 2 trial in lung cancer.


Strategic application domain: Human Medicine

Application market: Oncology

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide, Immunotherapy

Created on march 9th, 2010 - 5 employees



Espace Europeen, Bat G, 15 chemin du Saquin 69130 Ecully



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.